Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Subspecialties

Newsbytes

September 2025—In his previous role as a pathologist at Seattle’s Virginia Mason Medical Center, Dick Hwang, MD, PhD, was looking for a way to make his life—and his colleagues’ lives—easier. So he reached for something he hadn’t used in a while: his doctorate in computational biology. It was 2014, and Virginia Mason’s pathology group had just rolled out M*Modal Fluency Direct speech-recognition software as an optional tool for dictating diagnostic data. Dr. Hwang and many of his colleagues embraced the new software, but they soon realized that it meant they’d be spending a lot of time editing and formatting data. Entering a final diagnosis required, for example, typing “1.{tab}{caps lock},” dictating “cecum and ascending colon comma polypectomy,” then typing “:{caps lock}{return}{backspace}A.{tab}”—just as a start.

Put It on the Board

September 2025—CAP president Donald Karcher, MD, in a July 25 letter urged the chairs and ranking members of the Senate and House appropriations subcommittee on labor, health and human services, education, and related agencies to apply pressure to obligate and award already approved funding for the CDC Division of Cancer Prevention and Control. “Even though Congress approved FY 2025 funding in March, the CDC has not issued notice of awards to provide funding to state and local health departments for the remaining FY 2025 funds,” he said. “State and local health departments are challenged to continue their work without knowing if they will be reimbursed. State health departments and grantees are on the verge of shutting down programs and furloughing staff.”

Letters

September 2025—It has come to the attention of the American Association of Pathologists’ Assistants that some pathologists and pathology fellows assume the pathologists’ assistant profession is widely licensed, since we are comparable to the nationally licensed physician associates. This is a misconception that I, chair of the AAPA legislative subcommittee, and the AAPA Board of Trustees would like to address with the pathology community.

Big interest, gaps in early pancancer testing

August 2025—There’s the cart before the horse. There are certain equines that should not be flogged; others should not be backed. There’s closing the stable door at an unfortunate time.

The fine points of NIFTP interpretation

August 2025—The noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, is an entity that was introduced nearly a decade ago. It’s a lesion no longer considered malignant and instead grouped with more indolent lesions, owing to its observed indolent clinical behavior.

Study reveals extrachromosomal DNA’s impact

August 2025—Detection of extrachromosomal DNA in a tumor was found in a study published late last year to be associated with tumor stage, more prevalent after targeted and cytotoxic therapy, and associated with metastases and shorter overall survival.

Capillary and venous blood equivalence studied for routine tests

August 2025—For routine diagnostic testing, capillary blood is a reliable alternative to venous blood, say the authors of a study published in May. The study was led by Babson Diagnostics, of Austin, Tex., an independent startup spun out of Siemens Healthineers. Babson says it’s the first to validate capillary blood as a viable option for routine testing.

D-dimer reporting, INR among the variables that matter

August 2025—Anticoagulant interference, INR calculation, and D-dimer reporting are among the coagulation testing analytical and postanalytical variables that merit caution. Andrew Goodwin, MD, and Eric Salazar, MD, PhD, in a CAP24 session dug into why and what the requirements are, including for viscoelastic testing.

A blood management road map in WHO’s latest guidance

August 2025—The World Health Organization released new guidance this spring to provide aid in implementing patient blood management programs and toolkits to support blood health and patient safety at various resource levels. “It’s the job of the clinician to make the right decisions about blood use at the right time. Patient blood management programs help them do that,” says Sherri Ozawa, MSN, RN, a coauthor of the WHO guidance. “What documents like this and others do is help make the bridge between what laboratory professionals already know and changing clinical practice.” Ozawa is director of patient blood management operations for hc1 of Indianapolis, Ind., a company that optimizes laboratory data to improve clinical practice, enabling better patient care, streamlining operations, and reducing costs.

The quest to detect hemolysis in POC blood gas testing

August 2025—Werfen launched in July 2024 its Gem Premier 7000 with iQM3 blood gas testing system. One year in, CAP TODAY publisher Bob McGonnagle spoke with Werfen’s Kristina Powell, Ken Huffenus, and Sofia Afonso for the latest on that and about what Werfen showcased at the ADLM meeting last month.

MARKETPLACE

TRENDING